Grifols (GIKLY) Research & Development (2011 - 2018)
Grifols (GIKLY) reported Research & Development of $69.6 million for Q2 2018, up 1.37% on a YoY basis from $68.6 million in Q2 2017, and up 1.37% quarter-over-quarter from $68.6 million in Q2 2017.
Grifols (GIKLY) Research & Development (2011 - 2018) Analysis & Trends
Grifols has reported Research & Development for 7 years, with the latest figure at $69.6 million in Q2 2018.
- For the quarter ending Q2 2018, Research & Development rose 1.37% year-over-year to $69.6 million; the trailing twelve-month figure through Jun 2018 stood at $571.5 million (up 2.4% YoY), and the FY2025 full-year result was $495.9 million, up 20.85% from the prior year.
- Research & Development for Q2 2018 stood at $69.6 million, up from $68.6 million in the prior quarter.
- The five-year high for Research & Development was $375.0 million in Q4 2016, with the low at -$57.5 million in Q1 2015.
- Historically, Research & Development has averaged $83.0 million across 4 years, with a median of $58.6 million in 2015.
- The largest YoY upside for Research & Development was 550.27% in 2016 against a maximum downside of 4.2% in 2016.
- Grifols' Research & Development stood at $57.7 million in 2015, then jumped by 550.27% to $375.0 million in 2016, then slumped by 81.7% to $68.6 million in 2017, then gained by 1.37% to $69.6 million in 2018.
- The last three Research & Development figures came in at $69.6 million (Q2 2018), $68.6 million (Q2 2017), and $375.0 million (Q4 2016), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn | -2.28 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn | 3.51 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn | 3.53 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn | 2.47 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn | 12.59 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn | 1.72 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn | 1.37 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn | 2.49 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn | 2.65 Bn |
| 10 | Grifols | - | - | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2018 | 69.56 Mn |
| Jun 30, 2017 | 68.62 Mn |
| Dec 31, 2016 | 374.96 Mn |
| Sep 30, 2016 | 58.39 Mn |
| Jun 30, 2016 | 56.14 Mn |
| Dec 31, 2015 | 57.66 Mn |
| Sep 30, 2015 | 60.28 Mn |
| Jun 30, 2015 | 58.59 Mn |
| Mar 31, 2015 | -57.53 Mn |
| Sep 30, 2013 | 42.12 Mn |
| Jun 30, 2013 | 38.08 Mn |
| Mar 31, 2013 | 38.70 Mn |
| Dec 31, 2012 | -278.59 Mn |
| Sep 30, 2012 | 39.60 Mn |
| Jun 30, 2012 | 39.02 Mn |
| Mar 31, 2012 | 37.15 Mn |
| Dec 31, 2011 | 41.74 Mn |
| Sep 30, 2011 | 39.92 Mn |
| Jun 30, 2011 | -26.87 Mn |
| Mar 31, 2011 | -15.71 Mn |